Research progress of HHLA2 in malignant tumor / 中国免疫学杂志

ABSTRACT

With in-depth study on tumor pathogenesis in recent years,immunotherapy has gained breakthroughs,and Pembrolizumab,Nivolumab and other drugs,which are represented by programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1),have been approved for clinical use.Both human endogenous retrovirus subfamily H long terminal repeat associating protein 2 (HHLA2) and PD-L1 belong to B7 family and are homologous.They are highly expressed in various solid malignant tumors and are very likely to be another significant immunoassay and therapeutic target in succession to PD-L1.Research progress of HHLA2 in malignant tumors will be reviewed.